

**Supplemental Material: Table I. Baseline Characteristics by Intervention Group (Intent-To-Treat Population)**

Characteristic		Total (N=148)	Intervention Group	
			LDMTX (N=74)	Placebo (N=74)
Age (years)	Median (Q1, Q3)	54 (50, 59)	55 (51, 60)	53 (49, 56)
Sex	M	137 (93%)	68 (92%)	69 (93%)
	F	11 (7%)	6 (8%)	5 (7%)
CD4+ T-cells (/mm <sup>3</sup> )	Median (Q1, Q3)	726 (550, 925)	684 (538, 883)	731 (560, 948)
CD8+ T-cells (/mm <sup>3</sup> )	Median (Q1, Q3)	830 (573, 1075)	831 (538, 993)	829 (596, 1136)
10-year ASCVD risk (%)	Median (Q1, Q3)	8.5 (5.1, 12.9)	9.4 (6.0, 14.1)	7.9 (5.1, 11.7)
Smoking history	Never Smoked	57 (39%)	32 (44%)	25 (34%)
	>1-5 years	7 (5%)	3 (4%)	4 (5%)
	>5-10 years	7 (5%)	1 (1%)	6 (8%)
	>10 years	75 (51%)	37 (51%)	38 (51%)
Weight (kg)	Median (Q1, Q3)	85.7 (75.5, 96.9)	88.2 (77.2, 98.7)	84.3 (74.4, 93.3)
Total cholesterol (mg/dL)	Median (Q1, Q3)	175.0 (157.0, 208.5)	181.5 (157.0, 216.0)	172 (157, 192)
High-density lipoprotein cholesterol (mg/dL)	Median (Q1, Q3)	44 (36, 56)	47 (38, 59)	42.5 (35.0, 54.0)
Glucose (mg/dL)	Median (Q1, Q3)	93 (86, 102)	94 (87, 104)	92 (84, 101)
C-reactive protein (mg/L)	Median (Q1, Q3)	2.2 (1.1, 4.3)	2.4 (1.3, 5.0)	2.0 (1.0, 4.1)
D-dimer (ng/ml)	Median (Q1, Q3)	143.5 (98.8, 193.5)	151.5 (111.2, 220.1)	140.5 (90.4, 171.2)
Lipid-lowering medication use	Yes	93 (63%)	46 (62%)	47 (64%)
	No	55 (37%)	28 (38%)	27 (36%)
Antihypertensive medication use	Yes	103 (70%)	50 (68%)	53 (72%)
	No	45 (30%)	24 (32%)	21 (28%)
Hypoglycemic medication use	Yes	32 (22%)	14 (19%)	18 (24%)
	No	116 (78%)	60 (81%)	56 (76%)
Brachial artery flow-mediated dilation (%)	Median (Q1, Q3)	3.4 (2.1, 4.8)	3.5 (2.2, 4.8)	3.1 (2.0, 4.6)
Brachial artery grayscale median (u)	Median (Q1, Q3)	75.9 (63.7, 89.0)	74.8 (64.3, 86.8)	77.7 (62.1, 93.5)
Brachial artery gray level difference statistic-contrast (u)	Median (Q1, Q3)	120.4 (80.2, 184.1)	135.0 (74.5, 195.2)	117.1 (82.6, 166.5)
Brachial artery entropy (u)	Median (Q1, Q3)	4.2 (4.0, 4.4)	4.2 (4.0, 4.4)	4.2 (4.0, 4.3)

**Supplemental Material: Table II. Brachial Artery Grayscale Measures by Intervention Group at Baseline and Changes at Week 24 (Intent-To-Treat Population)**

		<b>Total (N = 176)</b>	<b>LDMTX (N = 86)</b>	<b>Placebo (N = 90)</b>	<b>Group Difference</b>
<b>Grayscale median</b>					
Week 0	N	162	83	79	
	Median	75.1	74.1	77.4	
	(Q1, Q3)	(62.2, 88.5)	(63.1, 86.8)	(62.1, 93.5)	
$\Delta$ to Week 24	N	148	74	74	
	Median	0.16	-0.81	1.30	
	(Q1, Q3)	(-11.7, 10.7)	(-11.5, 8.74)	(-12.5, 11.0)	
	P-value	0.55	0.62	0.74	0.89
<b>Gray level difference statistic-contrast</b>					
Week 0	N	162	83	79	
	Median	120.4	126.4	118.2	
	(Q1, Q3)	(78.3, 185.3)	(69.9, 195.2)	(82.6, 173.4)	
% $\Delta$ to Week 24	N	148	74	74	
	Median	4.8%	13.0%	-1.7%	
	(Q1, Q3)	(-21.8, 51.1)%	(21.3, 58.6)%	(-28.2, 39.3)%	
	P-value	0.09	<b>0.010</b>	0.82	0.06
<b>Entropy</b>					
Week 0	N	162	83	79	
	Median	4.18	4.18	4.20	
	(Q1, Q3)	(4.00, 4.39)	(3.96, 4.39)	(4.02, 4.39)	
$\Delta$ to Week 24	N	148	74	74	
	Median	0.02	0.07	0.01	
	(Q1, Q3)	(-0.11, 0.19)	(-0.09, 0.23)	(-0.11, 0.14)	
	<b>P-value</b>	<b>0.029</b>	<b>0.017</b>	0.59	0.13